Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer

Advances in Pharmacology

Volumn 35, Issue C, 1996, Pages 281-306

  Denmeade, Samuel R ^a   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRODRUG; SESQUITERPENE; THAPSIGARGIN;

APOPTOSIS; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; REVIEW;

APOPTOSIS; GENE EXPRESSION; HUMANS; MALE; NEOPLASM METASTASIS; PRODRUGS; PROSTATIC NEOPLASMS; SESQUITERPENES; THAPSIGARGIN;

EID: 0029683196     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60278-1     Document Type: Article

References (78)

1. Berges R.S., Furuya Y., Remington L., English H.F., Jacks T., and Isaacs J.T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8910-8914
2. Berges R., and Isaacs J.T. Programming events in the regulation of cell proliferation and death. Clin. Chem. 39 (1993) 2
3. Berges R.S., Vukanovic J., Epstein J.I., et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1 (1995) 473-480
4. Brüne B., Hartzell P., Nicotera P., and Orrenius S. Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp. Cell Res. 195 (1991) 323
5. Buttyan R., Zakeri Z., Lockshin R., and Wolgemuth D. Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol. Endocrinol. 2 (1988) 650
6. Buttyan R., Olsson C.A., Pintar J., Chang C., Bandyk M., Ng P.-Y., and Sawczuk I.S. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol. Cell Biol. 9 (1989) 3473
7. Carter H.B., and Isaacs J.T. Experimental and theoretical basis for hormonal treatment of prostatic cancer. Semin. Urol. 4 (1988) 262
8. 1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis. J. Biol. Chem. 262 (1987) 11901
9. 2+ ATPase. FEBS Lett. 335 (1993) 345
10. Christensen S.B., Norup E., and Rasmussen U. Chemistry and structure-activity relationship of the histamine secretagogue Thapsigragin and related compounds. In: Krogsgaard-Larsen P., Brogger Christensen S., and Kofod H. (Eds). "Natural Products and Drug Development" (1993), Copenhagen, Denmark:, Munksgaard 405-418 1984.
11. Christensson A., Laurell C.B., and Lilja H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194 (1990) 755
12. Chung L.W.K., and Cotley D.S. Biochemical characterization of prostatic nuclei I. androgen-induced changes in nuclear proteins. Biochim. Biophys. Acta 247 (1971) 570
13. Coffey D.S., Shimazaki J., and Williams-Ashman H.G. Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch. Biochem. Biophys. 124 (1968) 184
14. Crawford E.D., et al. A control randomized trial of Leuprolide with and without flutamide in prostatic cancer. N. Engl. J. Med. 321 (1989) 419
15. Dowd D.R., MacDonald P.N., Komm B.S., Haussler M.R., and Miesfeld R. Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J. Biol. Chem. 266 (1991) 18423
16. English H.F., Drago J.R., and Santen R.J. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. The Prostate 7 (1985) 41
17. English H.F., Kyprianou N., and Isaacs J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15 (1989) 233
18. Evans G.S., and Chandler J.A. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen replacement upon basal and secretory cell proliferation. Prostate 11 (1987) 339
19. Fesus L., Thomazy V., and Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett. 224 (1989) 104
20. Folkman J. What is the evidence that tumors are angiogenesis-dependent?. J. Natl. Cancer Inst. 82 (1990) 4
21. Furuya Y., and Isaacs J.T. Differential gene regulation during programmed death (Apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133 (1993) 2660-2666
22. Furuya Y., and Isaacs J.T. Proliferation-dependent vs independent programmed cell death of prostatic cancer cells involves distinct gene regulation. The Prostate 25 (1994) 301
23. Furuya Y., Lundmo P., Short A.D., Gill D.L., and Isaacs J.T. The role of calcium pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res. 54 (1994) 6167
24. Furuya Y., Walsh J.C., Lin X., Nelson W.G., and Isaacs J.T. Androgen ablation induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 136 (1995) 1898-1906
25. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of Programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493
26. Helpap B., Steins R., and Bruhl P. Autoradiographic in vitro investigations on prostatic tissue with C-14 and H-3 thymidine double labeling method. Beitr. Pathol. Anat. Allg. Pathol. 151 (1974) 65
27. Horm J., and Sondik E. Person-years of life lost due to cancer in the United States 1970 and 1984. Am. J. Public Health 79 (1989) 1490
28. Ichikawa T., Lamb J.C., Christensson P.J., Hartley-Asp B., and Isaacs J.T. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52 (1992) 3022
29. Isaacs J.T. Cellular factors in the development of resistance to hormonal therapy. In: Bruchovsky N., and Goldie J. (Eds). "Drug and Hormone Resistance in Neoplasia I" (1981), CRC Press, Boca Raton. 139-156
30. Isaacs J.T. Hormonally responsive vs unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and G rat prostatic adenocarcinoma. Cancer Res. 42 (1982) 5010
31. Isaacs J.T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5 (1984) 1
32. Isaacs J.T. Antagonistic effect of androgen on prostatic cell death. The Prostate 5 (1984) 545
33. Isaacs J.T. Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Res. 49 (1989) 6290
34. Isaacs J.T., and Coffey D.S. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studies in the Dunning R-3327 H adenocarcinoma. Cancer Res. 41 (1981) 5070
35. Isaacs J.T., and Lundmo P.I. Chemotherapeutic induction of programmed cell death in non proliferating prostate cancer cells. Proc. Am. Assoc. Cancer Res. 33 (1992) 588
36. Isaacs J.T., Lundmo P.I., Berges R., Martikainen P., Kyprianou N., and English H.F. Androgen regulation of programmed death of normal and malignant prostatic cells. J. Androl. 13 (1992) 457
37. Kerr J.F.R., Wyllie A.H., and Currie A.R. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer 26 (1972) 239
38. Kerr J.F.R., and Searle J. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch. B Cell. Pathol. 13 (1973) 87
39. Kyprianov N., and Isaacs J.T. Biological significance of measurable androgen levels in the rat ventral prostate following castration. The Prostate 10 (1987) 313
40. Kyprianou N., and Isaacs J.T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122 (1988) 552
41. Kyprianou N., and Isaacs J.T. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 123 (1988) 2124
42. Kyprianou N., and Isaacs J.T. Thymine-less death in androgen independent prostatic cancer cells. Biochem. Biophys. Res. Commun. 165 (1989) 73
43. Kyprianou N., and Isaacs J.T. Expression of transforming growth factor-β in the rat ventral prostate during castration induced programmed cell death. Mol. Endocrinol. 3 (1989) 1515
44. 2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13 (1988) 103
45. Kyprianov N., English H.F., and Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50 (1990) 3748-3753
46. Lepor H., Ross A., and Walsh P.C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol. 128 (1982) 335
47. Lilja H., Abrahamsson P.-A., and Lundwall A. Semenogelin, the predominant protein in human semen. J. Biol. Chetn. 264 (1989) 1894
48. 1-antichymotrypsin. Clin. Chem. 37: 618.
49. Lowe S., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362 (1993) 847
50. Lytton J., Westlin M., and Haley M.R. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J. Biol. Chem. 266 (1991) 17067
51. Martikainen P., and Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. The Prostate 17 (1990) 175
52. 1 on proliferation and death of rat prostatic cells. Endocrinology 127 (1990) 2963
53. Martikainen P., Kyprianou N., Tucker R.W., and Isaacs J.T. Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Res. 51 (1991) 4693
54. Meyers J.S., Sufrin G., and Maring S.A. Proliferation activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol. 128 (1982) 1353
55. Montpetit M.L., Lawless K.R., and Tenniswood M. Androgen repressed messages in the rat ventral prostate. Prostate 8 (1986) 25
56. Nemoto R., Hattori K., Uchida K., et al. S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling. Cancer 66 (1990) 509
57. Papsidero L.D., Kuriyama M., Wang M.C., et al. Prostate antigen: A marker for human prostate epithelial cells. J. Natl. Cancer Inst. 66 (1981) 37
58. Pegg A.E., Lockwood D.H., and Williams-Ashman H.G. Concentrations of putrescine and polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem. J. 117 (1970) 17
59. Prout G.R., Leiman B., Daly J.J., MacLoughlin R.A., et al. Endocrine changes after diethylstilbestrol therapy. Urology 7 (1976) 148
60. Quarmby V.E., Beckman Jr. W.C., Wilson E.M., and French F.S. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol. Endocrinol. 1 (1987) 865
61. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin. Oncol. 15 (1988) 371
62. Rasmussen U., Christensen S.B., and Sandberg F. Thapsigargin and thapsigargicin, two new histamine liberators from Thapsia garganica. L. Acta. Phartn. Suec. 15 (1978) 133
63. Sadi M.V., and Barrack E.R. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 67 (1991) 3065
64. Shackney S.E., McCormack G.W., and Cuchural G.J. Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Ann. Intern. Med. 89 (1978) 107
65. Sinha A.A., Blackhard C.E., and Seal U.S. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer 40 (1977) 2836
66. Stiens R., and Helpap. Regressive changes in the prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis. Pathol. Res. Pract. 172 (1981) 73
67. Snyder R.D. Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem. J. 260 (1989) 697
68. 2+-ATPase. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 2466
69. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N. Engl. J. Med. 311 (1984) 1281-1286
70. Tubiana M., and Malaise E.P. Growth rate and cell kinetics in human tumors: Some prognostic and therapeutic implications. In: Symington T., and Carter R.L. (Eds). "Scientific Foundations of Oncology" (1976) 126-138
71. Umansky S.R., Korol B.A., and Nelipovich P.A. In vivo DNA degradation in thymocytes of γ-irradiated or hydrocortisone-treated rats. Biochim. Biophys. Acta 655 (1981) 9
72. Vukanovic J., Passaniti A., Hirata T., et al. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 53 (1993) 1833
73. Vukanovic J., and Isaacs J.T. Linomide inhibits ongiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res. 55 (1995) 1499
74. Watt K.W.K., Lee P.-J., Timkulu T.M., Chan W.-P., and Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 3166
75. Wingo P.A., Tong T., and Bolden S. Cancer statistics, 1995. CA Cancer J. Clin. 45 (1995) 8
76. Wyllie A.H., Morris R.G., Smith A.L., and Dunlop D. Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142 (1984) 66
77. Wyllie A.H., Kerr J.F.R., and Currie A.R. Cell death: The significance of apoptosis. Int. Rev. Cytol. 68 (1980) 251
78. Zimmerman M., Ashe B., Yurewicz E.C., and Patel G. Sensitive assays for trypsin, elastase, and chymotrypsin using new fluorogenic substrates. Anal. Biochem. 78 (1977) 47